SU2C — 2024 Annual Report

2 0 24 ANNUAL REP O RT

WE STAND TOGETHER

Stand Up To Cancer® (SU2C) raises awareness and funds research to detect and treat cancers with the aspiration to cure all patients.

SU2C is a 501(c)(3) charitable organization and was initially launched in 2008 as a division of the Entertainment Industry Foundation. Established by media and entertainment leaders, SU2C utilizes these communities’ resources to engage the public in supporting a collaborative model of cancer research, to increase awareness about cancer prevention, and to highlight progress being made in the fight against the disease.

The American Association for Cancer Research is SU2C’s scientific partner.

Lily, survivor

2

DEAR FRIENDS, It is with deep gratitude and pride that I share SU2C’s 2024

When we stand against cancer, we do it together. This year, SU2C’s

annual report with you. This year, you took a stand against

awareness efforts and collaborations with the entertainment and sports

cancer with us, and your support made a profound impact

communities reached millions of people, reinforcing the importance of

on our shared goal of ending cancer as we know it.

cancer research and promoting early-stage detection through cancer

2024 was a pivotal year for SU2C. Building on the exceptional pace of research to date, we further refined our research

screenings. Private funding for scientific research is more critical today than ever, and it will take all of us to realize the possibilities ahead.

strategy with a key focus on early-stage detection

Our community is extraordinary, embodying the power of collaboration

and cancer interception. With the growing promise of

and our shared commitment to high-impact science. This year, we were

immunotherapies, liquid biopsy cancer screenings, anti-

delighted to welcome new experts to our Scientific Advisory Committee

cancer vaccines, and other critical advances, we now

who will play an important role in guiding our scientific strategy.

have more ways to catch cancer earlier and treat it more effectively, meaning millions more lives saved.

I am grateful to you for standing with us. Thanks to our donors,

In this year’s report, you’ll discover how our organization

for Cancer Research, we have made great strides.

made remarkable progress as a direct result of your support.

On behalf of all of us at SU2C, and our SU2C-funded

Our two innovation summits brought together leaders with

research teams making life-saving discoveries around

expertise in artificial intelligence (AI) as well as preventive

the world, thank you for supporting our mission.

and therapeutic vaccines to discuss new possibilities for cancer research and treatment. We also continued to forge a bold path forward with critical funding in 2024 for breast, gastroesophageal, pancreatic, pediatric, and rectal

collaborators, and our longstanding partner, the American Association

We are truly stronger together.

Warmly,

cancers, as well as sarcoma and other important areas of focus. We continue to evolve as science evolves.

Julian Adams, Ph.D. President and CEO 3

TOGETHER, WE FUELED

INNOVATION Our Year in Science

4

2024 was a year of considerable progress in cancer research.

We hosted our annual SU2C Scientific Summit and two crucial innovation summits. These events reflected our core goal of fostering collaboration, catalyzed important conversations about our scientific strategy, and helped us set a bold agenda for the future.

2024 SU2C Summits Since SU2C’s inception, our collaboration with the AACR has been instrumental to our progress. As SU2C’s trusted scientific partner, AACR plays a vital role in administering select SU2C-funded research teams and supporting our annual Scientific Summit, which brings together leading cancer experts from around the world. AACR also works closely with SU2C’s Scientific Advisory Committee to support our rigorous review process, helping to identify the most promising research proposals with the greatest potential to drive advances in cancer treatment and prevention. This synergistic relationship between SU2C and AACR helps propel both organizations’ shared mission to end cancer.

SU2C Scientific Summit 2024 JANUARY 26-29, 2024 | CORONADO, CA

SU2C’s 15th annual Scientific Summit, organized with support from AACR, combined collaboration and celebration along with deep appreciation for our researchers’ critical work. The event inspired and motivated our 300 Summit participants, including SU2C’s dedicated donors and patient advocates, and showcased our positive impact on patient outcomes. During the Scientific Summit, several new AACR-administered grants were awarded, including the Cless Family Gastric Cancer Innovation in Collaboration Award and two Phillip A. Sharp Innovation in Collaboration Awards.

5

TOGETHER, WE DROVE

BREAKTHROUGHS Our Year in Science

Our two innovation summits featured emerging possibilities in cancer research, such as harnessing the significant potential of AI as well as the potential of therapeutic vaccines.

AI in Cancer Research, Diagnosis, and Treatment MAY 3, 2024 | MOUNTAIN VIEW, CA

AI and machine learning are significantly enhancing clinicians’ ability to detect and treat cancer at earlier stages. At our first Innovation Summit of 2024, we convened 83 leading researchers, clinicians, and collaborators to discuss innovative work taking place today and define our vision for the future.

MARY’S STORY For five years, Mary shuffled from doctor to doctor seeking help for a lump in the soft tissue of her knee.

Repeatedly misdiagnosed as a lipoma

Detection Platforms and Vaccines NOVEMBER 3, 2024 | NEW YORK, NY

Early detection and anti-cancer vaccines hold substantial life-saving potential. If detected early, 90% of cancers are curable with current treatments.

Vaccines provide further possibilities to prevent

6

(a benign, fatty tissue growth), the lump continued to grow. Mary was initially referred to a surgeon to have it removed for cosmetic reasons, but after her consultation, she chose to delay surgery. When she returned to the surgeon, the bump had changed and she was sent for imaging. Scans revealed that

and treat cancers in the adjuvant setting.

the lump was actually stage 3 sarcoma: an aggressive soft tissue

This combination strategy was the subject

cancer. Mary was referred to a sarcoma specialist at the University

of our second Innovation Summit, where

of Michigan who offered her a place in Dr. Kirsch’s SU2C Catalyst®

90 experts came together to create

team’s immunotherapy clinical trial. Mary completed her last dose of

a roadmap for these new frontiers.

immunotherapy in June 2020 and is still cancer-free today.

Groundbreaking Clinical Trial Novel immunotherapy for soft-tissue sarcoma For the last three decades, breakthroughs have been sparse for soft tissue sarcomas, rare cancers that affect muscles, fat, and other connective tissues. A SU2C Catalyst Research Team comprising researchers from around the world announced clinical trial results that point to a new immunotherapy treatment option for two of the most common types of soft tissue sarcoma in adults. The study, led by David Kirsch, M.D., Ph.D., enrolled 127 patients across 20 hospitals in four countries. It introduced a new regimen of sarcoma care including the immunotherapy drug pembrolizumab (Keytruda) before, during, and after radiation therapy, and then again after surgery, which the team believed would enhance surgery’s efficacy and prevent recurrence. They were correct. This breakthrough study revealed that the use of immunotherapies reduced the risk of sarcoma relapse by 43% two years following treatment.

I truly believe that [my SU2C-supported clinical trial] saved my life. If people are offered a clinical study, I hope they agree to be in it because it does offer hope.”

7

Research Breakthrough First-of-its-kind clinical trial eliminated or shrunk melanoma tumors in 70% of patients Melanoma is the fifth most common cancer in the U.S., with 100,000 people diagnosed each year. A SU2C Catalyst Research Team tested a novel combination of immunotherapy and targeted therapy before and after surgery for melanoma, with noteworthy results. “We saw about two-thirds of the patients in one arm of the study had no remaining tumor at all at the time of their surgery,” Gunther, survivor

said lead investigator Matthew S. Block, M.D., Ph.D. Trial results were published in Nature Communications on February 16.

Defining the Moment in Cancer Research

Shortly after giving birth to a

New Publication by SU2C Science Team While cancer was once considered the “Emperor of All Maladies,” the acceleration of cancer research and treatment in the 20th and 21st centuries is unprecedented, pointing the way to a more hopeful future. The SU2C Science Team reflected on this trajectory and the still-greater possibilities for the future in a new publication titled “Cancer Treatment: Advances in the 21st Century and Beyond,” published in the

Drug Information Association Global Forum digital magazine on April 6, 2024.

KELLY’S STORY healthy baby boy in 2019, Kelly began experiencing worrying symptoms.

After several misdiagnoses, a colonoscopy revealed that she had stage 3 rectal cancer.

She was told her treatment protocol would include chemotherapy, radiation, and surgery, and that the after-effects of these treatments meant that she would most likely not be able to get pregnant again.

When Kelly reached out to schedule her first chemo

appointment, a research nurse told her about an immunotherapy You are invited to read the publication at SU2C.org/CancerAdvances.

clinical trial led by SU2C’s Colorectal Cancer Dream Team. After just nine treatments, Kelly’s tumor had completely disappeared. She is still in remission today and enjoying her growing family: in 2023, she and her husband celebrated the birth of their daughter, Maya, and they are expecting their third child in May 2025.

8

Without SU2C, my life wouldn’t look the way it does now. I wouldn’t have [my daughter] Maya or be waiting for baby number three. I’ll never win the lottery because I already have.”

9

TOGETHER, WE CATALYZED

BRILLIANT NEW RESEARCH New Science Funding in 2024

10

In 2024, SU2C provided new research grants, from foundational science that answers critical questions about cancer biology to clinical trials that test novel combination therapies. Our focus on big ideas and crossinstitutional collaboration advances the most promising work and helps get new treatments to patients faster.

New Funding Spotlight New SU2C Catalyst grant for AL amyloidosis research In November 2024, SU2C announced a new collaboration with Johnson & Johnson focused on AL amyloidosis, a rare disease associated with blood cancers such as multiple myeloma, lymphoma, and chronic lymphocytic leukemia.

Investigators participating in this effort via a SU2C Catalyst grant will explore a novel combination of two targeted therapies, teclistamab and daratumumab, for the treatment of AL amyloidosis.

11

Continued Funding SU2C-CRUK Pediatric Cancer New Discoveries Challenge

SU2C-CRUK Pediatric Cancer New Discoveries Challenge

PROJECT TITLE: Combinatorial Targeting of Oncogene-Driven

PROJECT TITLE: BRAINatomy: A Validated Anatomical Atlas of

Childhood Cancer

Childhood Neuroradiation Damage

LEADER: John Anderson, MBBS, MRCP, Ph.D., University College

LEADER: Martin McCabe, MB/BChir, Ph.D.,

London, Great Ormond

University of Manchester

Street Institute of Child Health

CO-LEADER: Thomas Merchant, D.O., Ph.D.,

CO-LEADER: Louis Chesler, M.D., Ph.D.,

St. Jude Children’s Research Hospital

Institute of Cancer Research SU2C’s long-standing strategic partnership with Cancer Research UK (CRUK) involves jointly funding international research, partially supported by CRUK through its Stand Up To Cancer campaign in the United Kingdom.

New Funding

12

Ziskin Prize 2024

SU2C Nina Nicolai Pancreatic Cancer

Phillip A. Sharp Innovation in

PROJECT TITLE: Improving Triple Negative

Innovation in Collaboration Award

Collaboration Award 2024

Breast Cancer (TNBC) Patient Outcome

PROJECT TITLE: Understanding How

PROJECT TITLE: Neoadjuvant Immune

with Personalized PARP Inhibitor-Based

KRAS Inhibition Reshapes the Antigen

Checkpoint Blockade in Mismatch Repair

Combination Therapy

Landscape in Pacreatic Cancer

Proficient Locally Advanced Rectal Cancer

LEADER: Marilyne Labrie, Ph.D., Université

LEADER: William Freed-Pastor, M.D., Ph.D.,

LEADERS: Andrea Cercek, M.D., and

de Sherbrooke

Dana-Farber Cancer Institute

Aparna Parikh, M.D.

CO-LEADER: Funda Meric-Bernstam, M.D.,

CO-LEADER: Steven Carr, Ph.D.,

LEAD INSTITUTION: Memorial Sloan Kettering

UT MD Anderson Cancer Center

Broad Institute

Cancer Center

Phillip A. Sharp Innovation in

Cless Family Foundation Gastric Cancer

Collaboration Award 2024

Innovation in Collaboration Award

PROJECT TITLE: Bacterial Whispers: Small-talk

PROJECT TITLE: Spatial Profiling and Organoids:

Shapes Mammalian Immunity

Immune Co-cultures to Develop Multimodal Predictive

LEADERS: Shawn Davidson, Ph.D., and

Biomarkers for CIN Gastro-esophageal Cancer

Ami Bhatt, M.D., Ph.D.

LEADERS: Karuna Ganesh, M.D., Ph.D., and

LEAD INSTITUTION: Northwestern University

Christina Curtis, Ph.D., M.Sc. LEAD INSTITUTION: Memorial Sloan Kettering Cancer Center

Ivy, survivor

SU2C Catalyst with Support from Merck

SU2C Convergence – Torrey Coast

PROJECT TITLE: Correlative study for project entitled

Foundation Research Team

“Pembrolizumab and Radiation Therapy to

PROJECT TITLE: Defining the Neoantigen

Improve Outcome in High-Risk Sarcoma”

and TCR Landscape to Inform Vaccine

LEADER AND INSTITUTION: Everett Moding, M.D., Ph.D.,

Approaches in Gastroesophageal Cancer

Stanford University

LEADER: Gad Getz, Ph.D., Broad Institute

Luke, survivor

SU2C Convergence – Torrey Coast

SU2C Maverick Award 2024

Foundation Research Team

PROJECT TITLE: LINE-1 as a Cancer Biomarker,

PROJECT TITLE: Optimal Vaccine Design

Contributor to Carcinogenesis, and Target

for Gastric Esophageal Cancer

for Cancer Chemoprevention

LEADER: Benjamin Greenbaum, Ph.D.,

RECIPIENT: Martin Taylor, M.D., Ph.D.,

Memorial Sloan Kettering Cancer Center

Brown University

Dan, survivor

13

Continued Support for Important Research SU2C Diversity in Early Development Clinical Trials Research Grants Program PROJECT TITLE: Enhancing Diversity in Early Phase Clinical Trials LEADER: Martin Edelman, M.D., Fox Chase Cancer Center PROJECT TITLE: Eliminating Enrollment Barriers to Early Phase Trials in a Diverse Population in Los Angeles County TEAM LEADER AND INSTITUTION: Anthony El-Khoueiry, M.D., University of Southern California PROJECT TITLE: Transferring Care to Enhance Access to Early-phase Cancer Clinical Trials LEADER: David Gerber, M.D., University of Texas Southwestern Medical Center PROJECT TITLE: Enhancing Diversity in Early Phase Clinical Trials in an Urban

Underserved Community LEADER: Walter Stadler, M.D., University of Chicago

Pancreatic Cancer Collective New Therapies Challenge PROJECT TITLE: Molecularly Targeted Radionuclide Therapy via the Integrin αυβ6 LEADER: Julie L. Sutcliffe, Ph.D., University of California at Davis

Photo, left to right: John D. Carpten, Ph.D., Vice Chairperson, Stand Up To Cancer Scientific Advisory Committee, Chairperson, Stand Up To Cancer Health Equity Committee and Arnold J. Levine, Ph.D., Vice Chair, Stand Up To Cancer Scientific Advisory Committee

14

15

TOGETHER, WE RAISED

OUR VOICES Celebrity Ambassadors, Public Awareness, and Media

SU2C’s events, Public Service Announcements (PSAs), and awareness campaigns bring life-saving information and inspiring stories to the public. This year, thousands of cancer survivors, celebrity ambassadors, television networks, corporate supporters, fellow nonprofit organizations, and individuals shared their talents and influence in support of our mission. Leveraging our growing presence in the gaming community and our enduring engagement with the entertainment industry, we elevated new voices and raised national awareness of the importance of cancer research.

16

Patient Ambassadors SU2C ran 12 PSAs across $185 million of donated ad space this year. Our PSAs serve a vital role in educating the public about the impact of cancer research and the importance of regular screenings to detect and treat cancer early.

They enable us to shine a light on the insights of our researchers and the stories of patients like Kelly Spill whose lives were saved due to their dedicated work.

Celebrity Ambassadors More than 100 actors, professional athletes, and other celebrities lent their time, voices, and platforms to raise crucial funds to advance cancer research: from Giving Tuesday to special social media initiatives and livestream fundraising events on popular television networks. These networks creatively integrated SU2C’s message into six popular TV shows, including Celebrity Name That Tune,

Who Wants to be a Millionaire, The Golden Bachelorette, 9-1-1: Lone Star, Jeopardy!, and Survivor.

Content Creators In 2024, the #SU2CStreamTeam and creator programs brought together groups of dedicated streamers who have a passion for raising funds and awareness for cancer research. The 4th annual #Up2Us streaming event brought together even more streamers and content creators across platforms to support SU2C’s mission. Additionally, an integrated awareness campaign with Pokémon GO generated millions of in-app impressions, amplifying SU2C’s reach. This year also marked the launch of #UniteAcrossPlatforms, SU2C’s first end-of-year streaming creator event, further solidifying its connection with Gen Z and Millennial audiences in the fight against cancer.

Folasade P. May, M.D., Ph.D., M.Phil.

SU2C Colorectal Cancer Health Equity Dream Team Co-Leader

17

In 2024, SU2C reached millions of people through our longstanding, strategic collaborations with Major League Baseball (MLB), American Airlines, Mastercard, and other valued supporters. Together with sports fans and players as well as our corporate supporters’ employees, we created highly visible and influential moments that united people in support of cancer research and made an enduring impact.

TOGETHER, WE REACHED

MILLIONS

18

Corporate Collaborations

Drone show at Hudson Yards created by Mastercard.

Major League Baseball As our founding donor, Major League Baseball and all 30 Clubs have steadfastly supported SU2C’s mission for 17 years. In 2011, MLB and SU2C created the first-ever Placard Moment™ at the MLB All-Star Game. Since then, the placard moments have been a staple of All-Star Games and the World Series, with hundreds of thousands of fans, players, umpires, and stadium staff pausing to honor a loved one affected by cancer. This year’s post-fifth-inning Placard Moment was as moving as ever: while thousands of fans stood with placards held high, survivors took the field with their own placards alongside former All-Stars Derek Jeter, Alex Rodriguez, and David Ortiz. After the All-Star Game, MLB with support from Mastercard, included in their social channels videos featuring MLB players sharing their placards and the names of loved ones they stand up for, as well as longer videos featuring Anthony Rizzo and Liam Hendriks sharing their personal cancer stories.

Mastercard Since 2010, SU2C has maintained a meaningful collaboration with Mastercard, which runs a successful annual campaign in support of our mission. In 2024, Mastercard produced a moving television spot created by cancer survivors as well as patients still in treatment and others whose lives have been impacted by cancer. Mastercard and SU2C used multiple channels to build awareness and raise funds for cancer research, including taking over the store windows at the New York City Saks Fifth Avenue, claiming a highly visible spot on Times Square video boards, and creating engaging ways for people to share who they stand up for on multiple social media platforms. During the MLB All-Star Game weekend, the campaign culminated in a beautiful and inspiring drone show at Hudson Yards, lighting the night and raising awareness for SU2C’s life-saving mission.

American Airlines In August, we launched another successful mileage campaign with American Airlines.

During this campaign, American team members and customers who donated a minimum of $25 to SU2C received American Airlines AAdvantage® bonus miles for every dollar given. This incentive included moving television spots featuring American team members, SU2C celebrity ambassador Rosario Dawson, and cancer survivor Pearce, who is also a former SU2C intern and patient ambassador and is pictured on the cover of this report.

19

TAKE YOUR STAND

We are deeply grateful to our committed community of supporters. Time and again, we have seen the powerful ways you come together to advance our mission through heartfelt tribute gifts, inspiring fundraising events, or long-term legacy commitments. We invite you to join us again this year as we continue to push the boundaries of science on behalf of patients with cancer.

Every gift, no matter the size or form, helps accelerate discoveries and brings us closer to cures. Thank you for being part of the SU2C community and for your unwavering support.

To learn more about the many ways you can support cancer research, please visit StandUpToCancer.org/Get-Involved.

20

Greta, survivor

Cancer research is important to our family because we have lost close family members over the years. While advancements in cancer treatments have been developed over the last 50 years, there is still a long way to go to find a cure for this awful disease.”

— S TEVE AND DAVID, Brenda’s husband and son

BRENDA’S LEGACY When she was diagnosed with cancer, Brenda was given a year or less to live. Instead, she lived for over two years and was able to attend her daughter’s wedding, while participating in clinical trials her doctor found through SU2C. Brenda’s courage inspired her son David to run in the New York half marathon in her honor, and to raise over $20,000 for SU2C, supported by his dad, Steve, and other friends and family.

For more information on how you can create your own fundraiser or make a gift in honor of a loved one, visit StandUpToCancer.org/Fundraise.

YOUR GENEROSITY MAKES CANCER RESEARCH BREAKTHROUGHS POSSIBLE. 21

22

A Preview of SU2C in 2025

WE’LL KEEP STANDING TOGETHER As we look to the year ahead, we move forward with the strong conviction that funding early-stage detection is essential to defeating cancer. When cancer is caught early, treatment is substantially more effective, and rates of remission and cure are much higher. We have set a bold goal to make early-stage detection the standard of care for all cancers. With continued investment, we believe it is achievable to reduce cancer deaths by 25% in five years and 50% in ten years.

23

In 2025, we will continue to move cancer research forward by facilitating scientific collaboration around big ideas, raising crucial research funds, and continuing to expand public awareness and support. Our focus on early-stage detection amplifies the power of our research funding mission, giving patients a head start on their treatment.

Great possibilities are ahead. Liquid biopsies can help bring early-stage cancer detection to millions of people, including medically-underserved communities, thanks to their simplicity and scalability. As AI transforms cancer detection and treatment, we can anticipate earlier diagnoses, more successful treatments, and many more lives saved. Therapeutic vaccines also hold significant promise, with positive results already unfolding in clinical trials. Personalized vaccines for melanoma and lung, colorectal, and pancreatic cancers can treat cancer, strengthen patients’ immune systems, and reduce recurrence.

Among our 2025 scientific and innovation summits will be a dedicated summit with a focus on Translating Data at the Limit of Detection in Cancers, discussing how big data can help detect minimal residual disease and help survivors stay in remission.

We will continue to raise awareness and funds through our Telecast, PSAs, and sports and entertainment events alongside our dedicated collaborators. We hope you’ll join us. You are a vital part of our movement.

TOGETHER, WE CAN CREATE

A WORLD WITHOUT CANCER.

THANK YOU FOR STANDING WITH US. 24

I wasn’t supposed to be able to walk or talk after my surgery, let alone graduate high school, move to California for college, or have the opportunity to work at SU2C [as an intern]. As a survivor, I feel a responsibility to be a voice for my friends who didn’t [get these chances], and I will continue to advocate in their honor and memory.”

— PEARCE, survivor and SU2C ambassador

25

2024 FINANCIALS REVENUE

Value of media donated to SU2C to air public service announcements.

1

kind contribution of In merchandise and services, including airline miles to support its programs.

2

Grant Program expenses are typically spread over several years and may not align with revenue received in any given year.

3

Information reflects unaudited financials.

Financial audit in progress at the time of printing.

Upon completion, audited financial statements will be available upon request.

26

EXPENSES

Marshella, survivor

27

SU2C LEADERSHIP SU2C envisions a future where every cancer is caught in time to be cured, and where survivors can enjoy life without fear of recurrence.”

BOARD OF DIRECTORS

FOUNDERS AND ADVISORS COMITTEE

Sherry Lansing

Katie Couric

Chair

Sherry Lansing

Jeff Bader

Secretary

Lisa Paulsen Rusty Robertson

Peter Seymour

Sue Schwartz

Treasurer

Pamela Oas Williams

Russell Chew Susan Desmond-Hellmann, M.D., M.P.H. William (Bill) Nelson, M.D., Ph.D. Phillip A. Sharp, Ph.D.

EXECUTIVE TEAM Julian Adams, Ph.D.

President and CEO Shawn Burke

Chief Financial Officer Dana Hirsch Lipman

General Counsel and Human Resources

28

Kathleen Lobb

Ellen Ziffren

In Remembrance Noreen Fraser Laura Ziskin

SCIENTIFIC ADVISORY COMMITTEE William G. Nelson, M.D., Ph.D.

Chairperson Johns Hopkins University John D. Carpten, Ph.D.

Vice Chairperson City of Hope National Medical Center Arnold J. Levine, Ph.D.

Vice Chairperson Institute for Advanced Study

MEMBERS Scott A. Armstrong M.D., Ph.D. Dana-Farber Cancer Institute Carlos L. Arteaga, M.D. UTSW Harold C. Simmons Cancer Center Michael A. Caligiuri, M.D. City of Hope National Medical Center Steven Carr, Ph.D. Broad Institute Jenny C. Chang, M.D. Houston Methodist Hospital Suzanne Dahlberg, Ph.D. Boston Children’s Hospital Alan D. D’Andrea, M.D. Dana-Farber Cancer Institute Luis A. Diaz, Jr., M.D. Memorial Sloan Kettering Cancer Center S. Gail Eckhardt, M.D. Baylor College of Medicine

29

MEMBERS continued Michael Fischbach, Ph.D. Stanford University Richard B. Gaynor, M.D. BioNTech Nancy F. Goodman, J.D. Kids v Cancer James L. Gulley, M.D., Ph.D. National Cancer Institute David G. Kirsch, M.D., Ph.D. Princess Margaret Cancer Centre Guillermina (Gigi) Lozano, Ph.D. University of Texas MD Anderson Cancer Center Tomas J. Philipson, Ph.D. The University of Chicago Lecia Sequist, M.D., M.P.H. Harvard Medical School Laura K. Shawver, Ph.D. Capstan Therapeutics Peter Sorger, Ph.D. Harvard Medical School David A. Tuveson, M.D., Ph.D. Cold Spring Harbor Laboratory Cancer Center

EMERITUS MEMBERS Elizabeth H. Blackburn, Ph.D. The University of California, San Francisco Lisa Diller, M.D. Dana-Farber Cancer Institute Judy Garber, M.D., M.P.H. Dana-Farber Cancer Institute Laurie H. Glimcher, M.D. Dana-Farber Cancer Institute William N. Hait, M.D., Ph.D. Janssen, Pharmaceutical Companies of Johnson & Johnso William G. Kaelin, Jr., M.D. Dana-Farber Cancer Institute

John D. Carpten, Ph.D.

Chairperson City of Hope National Medical Center Andrew T. Chan, M.D., M.P.H. Harvard Medical School Margaret Foli, Ph.D., M.D. (hc) American Association for Cancer Research Shawna Hudson, Ph.D. Rutgers Robert Wood Johnson Medical School Chanita Hughes-Halbert, Ph.D. Norris Comprehensive Cancer Center University of Southern California Elizabeth M. Jaffee, M.D.

Tak W. Mak, Ph.D.

Sidney Kimmel Comprehensive Cancer Center

University of Toronto

Johns Hopkins University

Andre Nussenzweig, Ph.D.

Guillermina (Gigi) Lozano, Ph.D.

National Cancer Institute

University of Texas MD Anderson Cancer Center

Roderic I. Pettigrew, Ph.D., M.D.

John Whyte, M.D., M.P.H.

Texas A&M University

WebMD

Cecil B. Pickett, Ph.D.

David R. Wilson, Ph.D.

Biogen Inc.

University of North Dakota

Carol L. Prives, Ph.D.

Karen M. Winkfield, M.D., Ph.D.

Columbia University

Meharry-Vanderbilt Alliance

Phillip A. Sharp, Ph.D.

Robert A. Winn, M.D.

Massachusetts Institute of Technology

Massey Cancer Center,

Arlene Sharpe, M.D., Ph.D. Harvard Medical School

30

HEALTH EQUITY COMMITTEE

Virginia Commonwealth University

THANK YOU

TO OUR GENEROUS SUPPORTERS

SU2C is grateful for the support of our committed donors, from corporations and industry to scientists and experts to dedicated philanthropists and family foundations. Many different sectors have joined us as crucial collaborators in advancing cancer research.

It takes all of us, standing together, to succeed.

LUMINARIES

CHAMPIONS

LEGACY CIRCLE

Bristol Myers Squibb

Chicago White Sox Charities

David Alden & Dina Al-Sabah

Genentech

Cless Family Foundation

Fisher Family

Lustgarten Foundation

The Estate of Barbara Hanania

Bob Judelson

Major League Baseball - Founding Donor

Fanconi Cancer Foundation

The Marcus Corporation Foundation

Mastercard

Farrah Fawcett Foundation

Arte & Carole Moreno, Angels Baseball

Jazz Pharmaceuticals

Foundation

Johnson & Johnson

Jerry & Martyl Reinsdorf

Laura Ziskin Family Trust

Peter & Sheel Seidler

Lew, Jean, & Kari Wolff

Bud & Sue Selig

Mirati Therapeutics

Kari Wolff

Providence

Lew & Jean Wolff

VISIONARIES American Airlines

HEROES Cancer Research UK Exact Sciences Merck Torrey Coast Foundation Van Andel Institute

Sara Schottenstein Foundation Thermo Fisher Scientific Jim Toth Visit Myrtle Beach Zentalis

CONTRIBUTORS American Head & Neck Society Eyemart Express Head and Neck Cancer Alliance Jerry Reinsdorf Night Nation Run Olivela Pancreatic Cancer Canada Trebek Family Foundation Upper Deck Golf Visual Eyes

Jason, survivor

Nate, survivor

31

$800 MM+ funds raised 3,100+ researchers funded 210+ collaborating institutions 8 fundraising televised specials 1,200 SU2C celebrity ambassadors 13 countries

TENS OF THOUSANDS OF LIVES SAVED GLOBALLY

32

Dan, survivor